| Objective:To explore weather A-FABP chemical inhibitor’s early intervention could prevent or delay the autoimmunity diabetes of NOD/ShiLtJ mice,in order to search for new therapeutic target for type1diabetes mellitus,Methods:4-weeks NOD/ShiLtJ female mice were devided into tow gruops randomly:A-FABP inhibitor group(n=5) and placebo group(n=5). According to the grouping, the mice were treated by oral gavage with vehicle including10%1-methyl-2-pyrrolidone and5%cremophor EL with5%ethanol in100ml of water or40mg/kg bodyweight of the A-FABP inhibitor dissolved in the vehicle for8weeks starting at4-weeks of age. Blood glucose were measured every week until30weeks. Time of onset were recorded and morbidity of diabetes were calculate. Serum were collected at week4,7,10,13,17and after the onset of diabetes, Fasting blood glucose(FBG) and serum A-FABP were detected. GTT were carried on at week17to evaluate the function of pancreatic beta cell.Results:(1) After ealy intervention of8weeks,serum A-FABP decreased gradually in inhibitor group, and was significantly lower than placebo group at17weeks(P<0.05).(2) Until30weeks, morbidity of inhibitor group was40%(2/5) and time of on set was182±45.5days in average, while morbidity of placebo group was100%(5/5), and time of onset was134.4±40.4days in average. Morbidity of inhibitor group was significantly lower than placebo group(P<0.05).(3) Postprandial blood glucose levels of inhibitor group were significantly lower than placebo group at week19-24,30(P<0.05).FBG level was significantly lower than placebo group at week17(P<0.05).(4) IPOGTT test show that glucose level of inhibitor group was lower than placebo group at30’,45’,60’,75’,90min(P<0.05).Conclusion:early intervention of A-FABP inhibitor in NOD/ShiLtJ mice for8weeks could decrease FBG and PBG level and improve the function of pancreas islet.It could also reduce morbidity of diabetes and delay the disease time of onset in NOD/ShiLtJ mice. |
PDF Full Text Request